Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance
R. SALANI, R. J. KURMAN, R. GIUNTOLI, G. GARDNER, R. BRISTOW, T.-L. WANG, I.-M. SHIH
International Journal of Gynecologic Cancer May 2008, 18 (3) 487-491; DOI: 10.1111/j.1525-1438.2007.01039.x